GPA33 and colorectal carcinoma: It has been reported that this antigen is heterogeneously expressed in CRC [19] and this heterogeneity might be a contributing factor in the failure of phase I/II clinical trials in therapeutic usage of monoclonal antibody against A33 during the past decade.